Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biomedical company Neoprobe has announced an exclusive agreement with Cardinal Health to market and distribute Lymphoseek, a radioactive mapping targeting agent used during lymph-node biopsies and other surgical procedures, through its network of more than 150 nuclear pharmacies.
Subscribe to our email newsletter
With this agreement, Cardinal Health will have exclusive US rights to distribute Lymphoseek for an initial term of five years following FDA clearance to market the product.
David Bupp, Neoprobe’s president and CEO, said: “Completing this agreement, coupled with the announcement of our recent discussions with the FDA regarding the Phase III clinical evaluation of Lymphoseek, are pivotal milestone events for Neoprobe. We believe this agreement meets our strategic objective of maximizing the long-term revenue and operating income opportunity that Lymphoseek represents for us.”